Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$8.2MCash on Hand
8.1mo Cash Runway
Follow SCNX by emailGet an email when SCNX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SCNX, unsubscribe in one click. Privacy
📣 What SCNX Says Is Next
second half of 2026 · “Together, we believe the continued commercialization of Arbli TM and the anticipated launch of REZENOPY TM will have a meaningful impact on our business performance during the second half of 2026,” added Mani.”
Company press release, May 22, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 3, 2026 ·
Shareholder vote Shareholders at the October 28, 2026 virtual annual meeting elected five directors, ratified CM3 Advisory as auditor for 2026, approved executive compensation on an advisory basis, and approved an adjournment proposal that was deemed unnecessary. Quorum was 35.3% of 41,064,146 eligible shares. Form 8-K · SEC filing
Oct 19, 2026 ·
Earnings Preliminary unaudited Q3 2026 revenue of about $1.22 million, up 256% from about $344,000 in Q2, driven by the REZENOPY launch and continued Arbli sales growth. Nasdaq confirmed the company regained compliance with the $1.00 minimum bid price, and the matter is closed. Form 8-K · SEC filing · Press release
Sep 18, 2026 ·
Shareholder vote Scienture Holdings will hold its 2026 annual meeting of stockholders on October 28, 2026, virtually at 11:00 a.m. Eastern Time. Shareholders will vote to elect five directors, ratify CM3 Advisory as auditor, approve executive compensation by advisory vote, and approve possible adjournment. Form DEF 14A · SEC filing
Sep 14, 2026 ·
Scienture Holdings posted a revised investor presentation to its website on September 14, 2026, for use in meetings with analysts and investors. The filing furnishes the presentation as Exhibit 99.1 and includes no new financial figures, trial data, or deal terms in the text provided. Form 8-K · SEC filing · Press release
Aug 20, 2026 ·
Earnings Reported Q2 2026 revenue of $343,639, up about 510% from $56,325 in Q1, with gross margin near 97.7%. Operating loss narrowed about 48% year-over-year to about $2.7 million, and cash, cash equivalents and restricted cash were about $11.2 million at June 30, 2026. Began commercial launch of REZENOPY. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SCNX holds $8.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $3M/quarter from operations,
an estimated runway of 8.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 4 months +40
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Aug 2025) +10
Going-concern doubt in the latest 10-Q +15These factors include, but are not limited to: ● Our limited amount of cash; ● The negative effect on our business and our ability to raise capital that is created by the fact that there is a substantial doubt about our ability to continue as a going concern; ● Our limited revenue generating operations, and risks of…10-Q, Nov 2026
Share count 1,787,953 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SCNX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCNX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.